Larimar Therapeutics, Inc. — Director's Dealing 2023

May 11, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Larimar Therapeutics, Inc. (LRMR)
CIK: 0001374690
Period of Report: 2023-05-09

Reporting Person: Truitt Joseph (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-05-09	Stock Option (Right to Buy)	$5.09	A	8300	Acquired	2033-05-09	Common Stock (8300)	Direct

Footnotes

F1: The options vest on the earlier of (a) May 9, 2024 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.